Sergolexole Explained

Sergolexole (developmental code name LY-281,067) is an ergoline derivative which acts as a selective antagonist of the serotonin 5-HT2 receptors. It has been used for various research applications, but was never developed for medical use.[1] [2] [3]

Notes and References

  1. Cohen ML, Fuller RW, Kurz KD, Parli CJ, Mason NR, Meyers DB, Smallwood JK, Toomey RE . 6 . Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067 . The Journal of Pharmacology and Experimental Therapeutics . 244 . 1 . 106–12 . January 1988 . 3335993 .
  2. Cohen ML, Parli CJ, Fuller RW . 5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067) . The Journal of Pharmacology and Experimental Therapeutics . 251 . 3 . 1006–11 . December 1989 . 2600800 .
  3. Koba S, Pakala R, Watanabe T, Katagiri T, Benedict CR . Vascular smooth muscle proliferation: synergistic interaction between serotonin and low density lipoproteins . Journal of the American College of Cardiology . 34 . 5 . 1644–51 . November 1999 . 10551718 . 10.1016/s0735-1097(99)00349-6 . 24224564 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sergolexole".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.